VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

Abstract Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi has enhanced clinical benefit in OC. To study drivers of efficacy when combining...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Francesca Bizzaro, Ilaria Fuso Nerini, Molly A. Taylor, Alessia Anastasia, Massimo Russo, Giovanna Damia, Federica Guffanti, Francesca Guana, Paola Ostano, Lucia Minoli, Maureen M. Hattersley, Stephanie Arnold, Antonio Ramos-Montoya, Stuart C. Williamson, Alessandro Galbiati, Jelena Urosevic, Elisabetta Leo, Ugo Cavallaro, Carmen Ghilardi, Simon T. Barry, Maria Rosa Bani, Raffaella Giavazzi
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Ovarian cancer
Patient-derived xenograft
PARP inhibitor
VEGF pathway inhibitor
BRCA
Olaparib
Diseases of the blood and blood-forming organs
RC633-647.5
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/5d13984571584daaa1864d9ef2ed329a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/5d13984571584daaa1864d9ef2ed329a

Ejemplares similares